FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

The HSE is going to help MS sufferers walk again



























THE HSE IS set to provide limited funding for Fampyra, a drug that helps sufferers of multiple sclerosis (MS) to walk.

The drug, known clinically as Fampridine and commercially as Fampyra, is to become eligible for reimbursement in some cases following a campaign by patients.

Patients were previously faced with having to pay as much as €400 a month for the drug.

The drug had been freely available to patients for two years under a clinical trial carried out by its manufacturer Biogen.

This came to an end at the beginning of July last year and since then patients have had to pay out of their own pockets for the drug.

Funding will now be available where a clinical response is demonstrated.
Speaking about the development, Ava Battles, chief executive of MS Ireland, said, “This news brings renewed hope to people with MS that have not been able to access or continue the treatment privately for financial reasons.

"MS Ireland has been working with people with MS, calling for access to this approved treatment on behalf of our members as it has shown increased mobility and allowed a quality of life that has previously been denied them due to the debilitating nature of this condition. We are thrilled that Fampyra is now accessible for those who respond to the drug.

The reimbursement date for the drug is set to be announced in the near future.
Dr Chris McGuigan, one of the investigators in the clinical trials for Fampyra, said that the drug is the only means available for treating the walking disability brought on by MS.

Story Source: The above story is based on materials provided by THEJOURNAL
Note: Materials may be edited for content and length


Go to Newer News Go to Older News